(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 9% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Ironwood Pharmaceuticals's revenue in 2024 is $442,735,000.On average, 4 Wall Street analysts forecast IRWD's revenue for 2024 to be $69,651,648,201, with the lowest IRWD revenue forecast at $68,246,490,528, and the highest IRWD revenue forecast at $70,625,725,978. On average, 4 Wall Street analysts forecast IRWD's revenue for 2025 to be $77,327,500,042, with the lowest IRWD revenue forecast at $74,626,598,220, and the highest IRWD revenue forecast at $81,081,839,664.
In 2026, IRWD is forecast to generate $90,693,011,708 in revenue, with the lowest revenue forecast at $79,987,704,414 and the highest revenue forecast at $103,715,882,165.